253 related articles for article (PubMed ID: 18811763)
1. Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy?
Lin C; Turner S; Gurney H; Peduto A
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):376-81. PubMed ID: 18811763
[TBL] [Abstract][Full Text] [Related]
2. Neurologic complications of prostate cancer.
Benjamin R
Am Fam Physician; 2002 May; 65(9):1834-40. PubMed ID: 12018806
[TBL] [Abstract][Full Text] [Related]
3. Spinal leptomeningeal metastases from prostate cancer.
Deinsberger R; Regatschnig R; Kaiser B; Bankl HC
Acta Neurochir (Wien); 2006 Apr; 148(4):467-71. PubMed ID: 16322903
[TBL] [Abstract][Full Text] [Related]
4. Intracranial dural metastases.
Nayak L; Abrey LE; Iwamoto FM
Cancer; 2009 May; 115(9):1947-53. PubMed ID: 19241421
[TBL] [Abstract][Full Text] [Related]
5. Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review.
Cone LA; Koochek K; Henager HA; Fausel R; Gade-Andavolu R; Potts BE; Jennings LM
Surg Neurol; 2006 Apr; 65(4):372-5, discussion 375-6. PubMed ID: 16531199
[TBL] [Abstract][Full Text] [Related]
6. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
7. [Carcinomatous meningitis from prostate cancer diagnosed by cerebrospinal fluid cytology and magnetic resonance image: a case report and review of the literature].
Yasufuku T; Shigemura K; Tanaka H; Matsumoto O; Nakano Y; Tanaka K; Fujisawa M
Hinyokika Kiyo; 2009 Jun; 55(6):361-5. PubMed ID: 19588872
[TBL] [Abstract][Full Text] [Related]
8. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal metastasis.
Chamberlain MC
Semin Neurol; 2010 Jul; 30(3):236-44. PubMed ID: 20577930
[TBL] [Abstract][Full Text] [Related]
11. Treatment of central nervous system metastases: parenchymal, epidural, and leptomeningeal.
Taillibert S; Hildebrand J
Curr Opin Oncol; 2006 Nov; 18(6):637-43. PubMed ID: 16988587
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
Martinez V; Mir O; Dômont J; Bouscary D; Goldwasser F
Anticancer Drugs; 2007 Feb; 18(2):233-5. PubMed ID: 17159610
[TBL] [Abstract][Full Text] [Related]
14. Secondary central nervous system metastases in children with neuroblastoma.
Astigarraga I; Lejarreta R; Navajas A; Fernandez-Teijeiro A; Imaz I; Bezanilla JL
Med Pediatr Oncol; 1996 Dec; 27(6):529-33. PubMed ID: 8888812
[TBL] [Abstract][Full Text] [Related]
15. Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer.
Bernstein WB; Kemp JD; Kim GS; Johnson VV
J Clin Oncol; 2008 Jul; 26(19):3281-4. PubMed ID: 18591564
[No Abstract] [Full Text] [Related]
16. [Brain metastasis and the carcinoembryonic antigen].
Noris-García E; Escobar-Pérez X
Rev Neurol; 2004 Feb 1-15; 38(3):267-70. PubMed ID: 14963857
[TBL] [Abstract][Full Text] [Related]
17. Neurologic complications of systemic cancer.
Newton HB
Am Fam Physician; 1999 Feb; 59(4):878-86. PubMed ID: 10068711
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapies in castrate-resistant prostate cancer.
Lassi K; Dawson NA
Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
[TBL] [Abstract][Full Text] [Related]
20. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.
Yang WQ; Senger DL; Lun XQ; Muzik H; Shi ZQ; Dyck RH; Norman K; Brasher PM; Rewcastle NB; George D; Stewart D; Lee PW; Forsyth PA
Gene Ther; 2004 Nov; 11(21):1579-89. PubMed ID: 15372068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
